SynVivo
SynVivo is a pioneering provider of cell-based microfluidic organ-on-chip platforms, delivering biologically realistic microenvironments for real-time study of cellular behavior, drug delivery, and drug discovery. Their proprietary technology bridges microfluidics and bioengineering, enabling advanced research in life sciences, disease modeling, and personalized medicine. SynVivo's chips support microvascular networks that closely mimic in vivo tissue conditions, validated by scientific research to more accurately reflect human biology than conventional culture methods. The platform is especially impactful for personalized cancer therapy, allowing patient-derived cells to be used for drug efficacy testing in a simulated tumor environment. SynVivo also distributes a wide range of high-quality primary cells and cell lines from various species, supporting research in immunology, cardiovascular, and cancer biology.
Industries
Nr. of Employees
small (1-50)
Patents
Products
3D tissue and organ-on-chip model suites (BBB, tumor, inflammation, lung ALI, toxicology)
Pre-configured microfluidic 3D tissue models representing blood–brain barrier, vascularized tumor microenvironment, inflammation assays, air–liquid interface lung models, and toxicology co-cultures for perfused assays and imaging.
Microfluidic chips in multiple geometries
Fabricated microfluidic devices in linear, bifurcating, idealized, and mapped microvascular network geometries to model distinct hemodynamic conditions for particle adhesion, transport, and cell migration studies.
Flow instrumentation and laboratory hardware for perfused assays
Instruments and controllers commonly used with microfluidic chips, including syringe pumps, pneumatic primers/controllers, stage-top incubators, and cell impedance analyzers to support controlled flow and environmental conditions during experiments.
Consumable accessories for flow-based assays
Consumables required to operate flow-based microfluidic assays such as laboratory tubing, clamps, syringes with Luer connections, and blunt-tip needles supplied in pack quantities.
3D tissue and organ-on-chip model suites (BBB, tumor, inflammation, lung ALI, toxicology)
Pre-configured microfluidic 3D tissue models representing blood–brain barrier, vascularized tumor microenvironment, inflammation assays, air–liquid interface lung models, and toxicology co-cultures for perfused assays and imaging.
Microfluidic chips in multiple geometries
Fabricated microfluidic devices in linear, bifurcating, idealized, and mapped microvascular network geometries to model distinct hemodynamic conditions for particle adhesion, transport, and cell migration studies.
Flow instrumentation and laboratory hardware for perfused assays
Instruments and controllers commonly used with microfluidic chips, including syringe pumps, pneumatic primers/controllers, stage-top incubators, and cell impedance analyzers to support controlled flow and environmental conditions during experiments.
Consumable accessories for flow-based assays
Consumables required to operate flow-based microfluidic assays such as laboratory tubing, clamps, syringes with Luer connections, and blunt-tip needles supplied in pack quantities.
Expertise Areas
- Organ-on-chip and perfused 3D tissue model development
- Microvascular network engineering and endothelial biology under flow
- Tumor microenvironment modeling and preclinical drug delivery assessment
- Blood–brain barrier modeling and functional permeability testing
Key Technologies
- Microfluidics for perfused cell culture
- Organ-on-chip platforms
- Microfabrication of PDMS and similar polymers
- Endothelialized vascular network culture
News & Updates
A publication highlighting the use of SynVivo's platform to study the effects of the NX210c peptide on blood-brain barrier integrity.
Research article utilizing SynVivo's technology to analyze neutrophil phenotypes in sepsis patients.
Study demonstrating the use of a biomimetic chip for evaluating monoclonal antibody bioavailability, leveraging SynVivo's platform.
SynVivo will participate in the SHOCK 2025 conference in Boston.
SynVivo will attend the BIO International 2025 event in Boston.
SynVivo will be present at the MPS World Summit 2025 in Belgium.
A publication highlighting the use of SynVivo's platform to study the effects of the NX210c peptide on blood-brain barrier integrity.
Research article utilizing SynVivo's technology to analyze neutrophil phenotypes in sepsis patients.
Study demonstrating the use of a biomimetic chip for evaluating monoclonal antibody bioavailability, leveraging SynVivo's platform.
SynVivo will participate in the SHOCK 2025 conference in Boston.
SynVivo will attend the BIO International 2025 event in Boston.
SynVivo will be present at the MPS World Summit 2025 in Belgium.